Abstract
The progressive reduction of the number of terminal hairs and the simultaneous increase in the number of vellus hairs (hair miniaturization) are the current explanation of human baldness. In a 2.5-year study on 43 male subjects with androgenetic alopecia (AGA), we found that oral finasteride augmented the total number of hairs by 55%, but failed to decrease the prevalence of vellus hairs. While our data may explain why, in AGA, hairs become progressively softer and combable, they cannot explain why areas of hair rarefaction develop. We propose that the longer duration and higher frequency of kenogen hairs are the real mechanism through which the scalp hairs rarefy.
References
1.
Van Neste
D
, Fuh
V
, Sanchez-Pedreno
P
, Lopez-Bran
E
, Wolff
H
, Whiting
D
, et al. Finasteride increases anagen hair in men with androgenetic alopecia
. Br J Dermatol
. 2000
Oct
;143
(4
):804
–10
.
[PubMed]
0007-09632.
Price
VH
, Menefee
E
, Sanchez
M
, Kaufman
KD
. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results
. J Am Acad Dermatol
. 2006
Jul
;55
(1
):71
–4
.
[PubMed]
0190-96223.
Hugh Rushton
D
, Norris
MJ
, Van Neste
D
. Hair regrowth in male and female pattern hair loss does not involve the conversion of vellus hair to terminal hair
. Exp Dermatol
. 2016
Jun
;25
(6
):482
–4
.
[PubMed]
0906-67054.
Sinclair
R
. Androgenetic alopecia. Modelling progression and regrowth
. Exp Dermatol
. 2016
Jun
;25
(6
):424
–5
.
[PubMed]
0906-67055.
Rebora
A
, Guarrera
M
. Kenogen. A new phase of the hair cycle?
Dermatology
. 2002
;205
(2
):108
–10
.
[PubMed]
1018-86656.
Guarrera
M
, Cipriani
C
, Rebora
A
. Delayed telogen replacement in a boy’s scalp
. Dermatology
. 1998
;197
(4
):335
–7
.
[PubMed]
1018-86657.
Guarrera
M
, Rebora
A
. Kenogen in female androgenetic alopecia. A longitudinal study
. Dermatology
. 2005
;210
(1
):18
–20
.
[PubMed]
1018-86658.
Courtois
M
, Loussouarn
G
, Hourseau
C
, Grollier
JF
. Hair cycle and alopecia
. Skin Pharmacol
. 1994
;7
(1-2
):84
–9
.
[PubMed]
1011-0283© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
